Evidence map›Paper›PMID 32527598›Full record

ArticleVaccine2020

Antenatal care service delivery and factors affecting effective tetanus vaccine coverage in low- and middle-income countries: Results of the Maternal Immunisation and Antenatal Care Situational analysis (MIACSA) project.

M L Giles, E Mason, F M Muñoz, A C Moran, P Lambach, S Merten, T Diaz, M Baye, M Mathai, J Pathirana and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Stakeholder Perceptions About Group B Streptococcus Disease and Potential for Maternal Vaccination in Low- and Middle-Income Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  17. Maternal RSV vaccine development. Where to from here?Human vaccines & immunotherapeutics · 2021
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 7 countries.

M L GilesDepartment of Obstetrics and Gynaecology, Monash University, Melbourne, Australia. Electronic address: michelle.giles@monash.edu.
E MasonLondon School of Hygiene and Tropical Medicine, London, UK.
F M MuñozSection Infectious Diseases, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
A C MoranEpidemiology, Monitoring and Evaluation (EME), Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland.
P LambachDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
S MertenSwiss Tropical and Public Health Institute and University of Basel, Basel, Switzerland.
T DiazEpidemiology, Monitoring and Evaluation (EME), Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland.
M BayeCoordinator of the National Program to Combat Maternal, Newborn and Child Mortality, Ministry of Public Health, Cameroon.
M MathaiDepartment of International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
J PathiranaMedical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
S RendellDepartment of Anthropology, University of Pennsylvania, Philadelphia, USA.
Ö TunçalpDepartment of Sexual and Reproductive Health and Research Including UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland.
J HombachDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
N RoosKarolinska Institutet, Department of Medicine, Clinical Epidemiology Division, Stockholm, Sweden.
World Health Organization · CHBaylor College of Medicine · USKarolinska Institutet · SELiverpool School of Tropical Medicine · GBLondon School of Hygiene & Tropical Medicine · GBMinistry of Public Health · CMMonash Health · AUSwiss Tropical and Public Health Institute · CHUniversity of Pennsylvania · USUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo map the integration of existing maternal tetanus immunization programmes within antenatal care (ANC) services for pregnant women in low- and middle-income countries (LMICs) and to identify and understand the challenges, barriers and facilitators associated with high performance maternal vaccine service delivery.

designA mixed methods, cross sectional study with four data collection phases including a desk review, online survey, telephone and face-to-face interviews and in country visits was undertaken between 2016 and 2018. Associations of different service delivery process components with protection at birth (PAB) and with country groups were established. PAB was defined as the proportion of neonates protected at birth against neonatal tetanus. Regression analysis and structural equation modelling was used to assess associations of different variables with maternal tetanus immunization coverage. Latent class analysis (LCA), was used to group country performance for maternal immunization, and to address the problem of multicollinearity.

settingLMICs.

resultsThe majority of LMICs had a policy on recommended number of ANC visits, however most were yet to implement the WHO guidelines recommending eight ANC contacts. Countries that recommended > 4 ANC contacts were more likely to have high PAB > 90%. Passive disease surveillance was the most common form of disease surveillance performed but the maternal and neonatal morbidity and mortality indicators recorded differed between countries. The presence of user fees for antenatal care and maternal immunization was significantly associated with lower PAB (<90%).

conclusionsRecommendations include implementing the current WHO ANC guideline to facilitate increased opportunities for vaccination during each pregnancy. Improved utilisation of ANC services by increasing the demand side by increasing the quality of services, reducing any associated costs and supporting user fee exemptions, or the supply side can also enhance utilisation of ANC services which are positioned as an ideal platform for delivery of maternal vaccines.

Indexed as

Prenatal CareTetanus ToxoidCross-Sectional StudiesDeveloping CountriesFemaleHumansImmunizationInfant, NewbornPregnancyVaccinationTetanus ToxoidAntenatal careMIACSAPregnancyTetanusVaccination

Identifiers

PMID32527598
PMCPMC7342001
OpenAlexW3035125627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.